BioSpace News Archive

Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), today announced that its peer-reviewed scientific manuscript entitled, “Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease (“AD”) in the Absence of Memantine” was published in the Journal of Alzheimer’s Disease.

The global professional services firm ZS announced today that it has entered into a strategic partnership through a supporting multimillion dollar investment in IgniteData, a U.K.-based digital health startup shaping the future of clinical research through its Archer technology.

Partnership between Temedica, a leading digital health and health insights company, and NOVENTI Health SE, the largest provider of enterprise resource planning (ERP) systems and claims management solutions for pharmacies in Germany

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET.

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in heart failure patients with preserved or mildly reduced ejection fraction.

I am pleased to welcome Erin Parsons to our Board of Directors,” said Brian M. Strem, Ph.D, President and CEO of Kiora.

Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer.

Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency.

Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California.